Author Archives: admin


Stem Cell Reconstructive Market top manufactures, Regions, Trends, Analysis, Types, Applications, Market Size and Forecasts 2019-2023 Bulletin Line -…

This report presents the worldwide Stem Cell Reconstructive market size (value, production and consumption), splits the breakdown (data status 2019 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2694263&source=atm

The report provides a valuable source of insightful data for business strategists and competitive analysis of Stem Cell Reconstructive Market. It provides the Stem Cell Reconstructive industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Stem Cell Reconstructive study provides comprehensive data which enhances the understanding, scope and application of this report.

segment by Type, the product can be split into Embryonic Stem Cell Adult Stem Cell Market segment by Application, split into Hospitals Research Institutes Others

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Stem Cell Reconstructive status, future forecast, growth opportunity, key market and key players. To present the Stem Cell Reconstructive development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell Reconstructive are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2694263&source=atm

Regional Analysis For Stem Cell Reconstructive Market:

For comprehensive understanding of market dynamics, the global Stem Cell Reconstructive market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Influence of the Stem Cell Reconstructive market report:

-Comprehensive assessment of all opportunities and risk in the Stem Cell Reconstructive market.

Stem Cell Reconstructive market recent innovations and major events.

-Detailed study of business strategies for growth of the Stem Cell Reconstructive market-leading players.

-Conclusive study about the growth plot of Stem Cell Reconstructive market for forthcoming years.

-In-depth understanding of Stem Cell Reconstructive market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Stem Cell Reconstructive market.

The report has 150 tables and figures browse the report description and TOC:

Table of Contents of Stem Cell Reconstructive Market

1 Study Coverage

1.1 Stem Cell Reconstructive Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Stem Cell Reconstructive Market Size Growth Rate by Type

1.4.2 Hydraulic Dredges

1.4.3 Hopper Dredges

1.4.4 Mechanical Dredges

1.5 Market by Application

1.5.1 Global Stem Cell Reconstructive Market Size Growth Rate by Application

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2694263&licType=S&source=atm

2 Executive Summary

2.1 Global Stem Cell Reconstructive Market Size

2.1.1 Global Stem Cell Reconstructive Revenue 2014-2025

2.1.2 Global Stem Cell Reconstructive Production 2014-2025

2.2 Stem Cell Reconstructive Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key Stem Cell Reconstructive Manufacturers

2.3.2.1 Stem Cell Reconstructive Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Stem Cell Reconstructive Product Offered

2.3.2.3 Date of Manufacturers Enter into Stem Cell Reconstructive Market

2.4 Key Trends for Stem Cell Reconstructive Markets & Products

3 Market Size by Manufacturers

3.1 Stem Cell Reconstructive Production by Manufacturers

3.1.1 Stem Cell Reconstructive Production by Manufacturers

3.1.2 Stem Cell Reconstructive Production Market Share by Manufacturers

3.2 Stem Cell Reconstructive Revenue by Manufacturers

3.2.1 Stem Cell Reconstructive Revenue by Manufacturers (2019-2025)

3.2.2 Stem Cell Reconstructive Revenue Share by Manufacturers (2019-2025)

3.3 Stem Cell Reconstructive Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

View post:
Stem Cell Reconstructive Market top manufactures, Regions, Trends, Analysis, Types, Applications, Market Size and Forecasts 2019-2023 Bulletin Line -...

Global Autologous Cell Therapy Market Revenue Outcome, Robust Vendors, and Investment Prospects – 3rd Watch News

Market Research Exploreoffers an exhaustive analysis on the Global Autologous Cell Therapy Market covering diverse significant factors that pose an impact on the current and forthcoming market conditions. The report elaborates on how the Autologous Cell Therapy market has been performing over the last five years at the global and regional levels. It also analyzes expected ups and downs in the market over the next five years. The report assists market players to operate their business wisely. Market scope, establishment, profitability, maturity, and growth prospects are also highlighted in the global Autologous Cell Therapy market report.

The report mainly emphasizes the market rivalry landscape, leading players profiles, segmentation, and industry environments which have been playing an integral role in posing impacts on market structure and profitability. It also includes a precise assessment of market share, size, demand, production, sales, and revenue that help intuit the financial health of the industry. It also illuminates various market dynamics such as changing product values, demand-supply variations, contemporary trends, pricing fluctuations, growth-driving forces, and unstable market conditions.

Sample Copy Global Autologous Cell Therapy Market Report 2020:https://www.marketresearchexplore.com/report/global-autologous-cell-therapy-industry-market-research-report/174131#enquiry

Extensive study of crucial Autologous Cell Therapy market segments:

The global Autologous Cell Therapy market has been segmented into a number of various vital segments such as types, applications, and regions. The report evaluates each segment at a minute level in view of its growth prospects, global demand, and current revenue. It also focuses on the segments that are exhibiting exponential growth during the year and help market players in selecting more profitable segments for their Autologous Cell Therapy businesses and precisely determine the actual needs and wants of their customer base.

Global Autologous Cell Therapy Market Competitive Assessment:

Expansive survey of Global Autologous Cell Therapy Market 2020

According to the report findings, the global Autologous Cell Therapy market report is extremely competitive and encouraging leading manufacturers and companies to execute various business and marketing strategies such as M&A activities, brand promotions, product launches, partnerships, and other expansions to perform comfortably in the relentless competition. The report further examines highlights new product developments, innovations, and technology adoptions done by the competitors in order to offer upgraded products and services in the global Autologous Cell Therapy market.

The report also provides a detailed financial assessment of leading market vendors and insights into the competencies and capacities of these companies to assist Autologous Cell Therapy market players for business expansions. The report also deeply analyzes effective product lines offered by various manufacturers and helps other participants to boost the quality of their products. Analysis based on forthcoming challenges and opportunities is also highlighted in the report, which will help Autologous Cell Therapy market players build lucrative strategies and grab all growth opportunities.

Significant Features of the Global Autologous Cell Therapy Market Report:

Connect with our industry experts at[emailprotected].

View post:
Global Autologous Cell Therapy Market Revenue Outcome, Robust Vendors, and Investment Prospects - 3rd Watch News

Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019 – Yahoo…

Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-Founder TSmeenk@Hemostemix.com 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the commercialization of ACP-01. There can be no assurances that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix which the Company believes are reasonable. These assumptions include, but are not limited to: the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trials or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any required or desired financings of Hemostemix, including TSX Venture Exchange acceptance and any third party consents; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Story continues

More here:
Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019 - Yahoo...

Global Brain Tumor Treatment Market Market Size, Trends, Technological Advancement And Growth Analysis With Forecast to 2027 – Cole of Duty

Global Brain Tumor Treatment Market presents insights into the present and upcoming industry trends, enabling the readers to identify the products and services, hence driving the enlargement and effectiveness. The research report provides a comprehensive breakdown of all the major factors impacting the market on a global and regional scale, including drivers, constraints, intimidation, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Get more information on Global Brain Tumor Treatment Market Research Report by requesting FREE Sample Copy @ https://www.globalmarketers.biz/report/business-services/2015-2027-global-brain-tumor-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146033#request_sample

Major Players:

Antisense Pharma Hoffmann- La Roche Merck & Co Bristol Myers Squibb Mankind Pharma Macleods Pharmaceutical Limited Novartis AG Dr. Reddys Laboratories Ltd Genetech U.S.A AstraZeneca plc Pfizer, Inc.

Global Brain Tumor Treatment Market research reports enlargement rates and the market value based on market dynamics, growth factors. Complete knowledge is based on the newest innovation in business, opportunities, and trends. In addition to SWOT examination by key suppliers, the report contains an all-inclusive market analysis and major players landscape.

The regional segmentation covers:

Segmentation by Type:

Tissue Engineering Immunotherapy Gene Therapy Other Therapies

Segmentation by Application:

Hospitals and Clinics Treatment Center Others

Do Inquiry Before Purchasing Report Here and Ask For Discount @: https://www.globalmarketers.biz/discount_inquiry/discount/146033

Report Objectives

Enquire Before Buying : https://www.globalmarketers.biz/report/business-services/2015-2027-global-brain-tumor-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146033#inquiry_before_buying

Table of Content:

The Global Brain Tumor Treatment Market

Chapter 1: Brain Tumor Treatment Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Brain Tumor Treatment Market Competition by Manufacturers

Chapter 3: Brain Tumor Treatment Production by Regions

Chapter 4: Production, By Types, Market share by Types

Chapter 5: Consumption, By Applications

Chapter 6: Comprehensive profiling and analysis of Manufacturers

Chapter 7: Manufacturing cost analysis

Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 9: Marketing Strategy Analysis, Distributors/Traders

Chapter 10: Brain Tumor Treatment Market Effect Factors Analysis

Chapter 11: Brain Tumor Treatment Market Forecast

Chapter 12: Conclusion of Brain Tumor Treatment Market

The Report has Tables and Figures Browse The Report Description and TOC @ https://www.globalmarketers.biz/report/business-services/2015-2027-global-brain-tumor-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146033#table_of_contents

Read this article:
Global Brain Tumor Treatment Market Market Size, Trends, Technological Advancement And Growth Analysis With Forecast to 2027 - Cole of Duty

Cell Culture Media Market 2019 to 2029 Key Insights and COVID-19 Business Impact – 3rd Watch News

Over the decades, there has been a notable increase in the prevalence of chronic diseases such as cancer all over the world. This is strengthening the focus of pharmaceutical manufacturers all over the world to develop more effective medicine and treatment methods for the same.

Increasing demand for biotechnological and biopharmaceuticals products using various cell culture lines is gaining importance. This increasing demand for cell culture will boost the growth of thecell culture media marketover the coming years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31338

Company Profiles

As such, the global cell culture media market was valued at US$ 2.4Bnin2018, and is expected to witness a healthy CAGR of7%over the forecast period (20192029).

Key Takeaways of Cell Culture Media Market Study

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/31338

Cell culture media not only helps in drug development but also collects extensive data that is valuable for future research. Rising demand for serum-free culture media will offer significant growth opportunities for the cell culture media market in the coming years,says a PMR analyst.

Trends in Cell Culture Media Technologies

There are many research and pipeline products that have the ability to treat chronic diseases. This is attributed to the current state of technology and more funding by government toward research & development activities. Also, rising awareness about cell culture-based vaccines and increasing demand for biopharmaceutical products will boost the growth of the cell culture media market.

Increasing collaborations between contract manufacturing organizations and key players will surge market growth further. Serum-free cell culture media, among other cell culture media, has the potential to grow at a relatively faster rate over the forecast period.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31338

More Valuable Insights on Cell culture media Market

Persistence Market Research offers a unique perspective and actionable insights on the cell culture media market in its latest study, presenting historical demand assessment of20142018and projections for20192029, on the basis of product (serum containing media, serum-free media, protein-free media, and chemically defined media), application (cancer research, biopharmaceuticals, regenerative medicine & tissue engineering, stem cell technologies, and others), and end user (biopharmaceutical companies, clinical research organizations, and academic research centers), across six regions.

Continue reading here:
Cell Culture Media Market 2019 to 2029 Key Insights and COVID-19 Business Impact - 3rd Watch News

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Professional Survey Report 2026: By Product, Application, Manufacturer, Sales and…

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Marketplace gives detailed Evaluation about all of the Important aspects regarding the marketplace. The analysis on Global Autologous Stem Cell and Non-Stem Cell Based Therapies economy, offers profound insights regarding the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace covering all of the significant characteristics of the marketplace. In addition, the report offers historical information with prospective prediction over the forecast period. Various critical aspects like market trends, earnings development patterns market stocks and supply and demand are contained in practically all of the market research document for every single business. A number of the vital facets analysed in the report contains market share, creation, key areas, earnings rate in addition to key players.

The analysis of different sections of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies market are also Covered in the study report. Along with this, for the prediction periods conclusion of variables such as market size and the competitive landscape of this sector is assessed in the report. On account of the rising globalization and digitization, there are new tendencies coming to the marketplace daily. The study report provides the detailed analysis of all of these tendencies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2632388&source=atm

Additionally, the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report also supplies the Latest tendencies in the Global Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace with the assistance of primary in addition to secondary research methods. Also, the analysis report on Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace gives a wide evaluation of the marketplace including market review, manufacturing, manufacturers, dimensions, cost, value, growth rate, earnings, prices, export, consumption, and sales revenue of this Global Autologous Stem Cell and Non-Stem Cell Based Therapies market. On the flip side, the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report also studies the industry standing for the prediction period. Nevertheless, this can help to grow the advertising opportunities throughout the world in addition to major market suppliers.

The key players covered in this study Fibrocell Science, Inc. Vericel Corporation Dendreon Corporation (Sanpower Group) Caladrius Biosciences, Inc. BrainStorm Cell Therapeutics Regeneus Ltd. Genzyme Corporation Pluristem Therapeutics Inc U.S. Stem Cell, Inc TiGenix (Takeda)

Market segment by Type, the product can be split into Autologous Stem Cell Therapy Non-Stem Cell Therapy Market segment by Application, split into Cancer Neurodegenerative Disorders Cardiovascular Disease Autoimmune Diseases Others

Market segment by Regions/Countries, this report covers North America Europe China Japan Mid East & Africa Australia

The study objectives of this report are: To analyze global Autologous Stem Cell and Non-Stem Cell Based Therapies status, future forecast, growth opportunity, key market and key players. To present the Autologous Stem Cell and Non-Stem Cell Based Therapies development in North America, Europe, China, Japan, Mid East & Africa and Australia. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Autologous Stem Cell and Non-Stem Cell Based Therapies are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2632388&source=atm

The Autologous Stem Cell and Non-Stem Cell Based Therapies market report provides useful insights for Every established and advanced players throughout the world. Additionally the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report provides accurate evaluation for the changing competitive dynamics. This study report includes a whole analysis of future expansion concerning the evaluation of this mentioned prediction interval. The Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report provides a thorough analysis of the technological advancement prognosis over time to be aware of the industry growth prices. The Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace report also has innovative analysis of the massive number of unique facets which are fostering or functioning in addition to regulating the Autologous Stem Cell and Non-Stem Cell Based Therapies marketplace development.

A systematized methodology can be utilized to create a Study on the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Sector. For the research of economy on the Conditions of study Approaches, these strategies are useful. All of the Information Regarding this Products, makers, vendors, clients and even more is covered in research reports. Various important factors like market trends, earnings Growth patterns market stocks and supply and demand are contained in virtually all The market study report for every single business. Adaptation of fresh thoughts and Accepting the most recent tendencies are a few the causes of virtually any markets growth. The Global Autologous Stem Cell and Non-Stem Cell Based Therapies market research report provides the profound understanding concerning the Areas in which the marketplace is impactful.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2632388&licType=S&source=atm

View post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Professional Survey Report 2026: By Product, Application, Manufacturer, Sales and...

Roddenberry Stem Cell Center | Gladstone Institutes

Stem cells that have the potential to develop into any type of cell in the body are called pluripotent. Pluripotent stem cells arise naturally in the early stages ofembryonic development. Induced pluripotent stem (iPS)cellsare adult cells that have been reprogrammed to take on the properties of embryonic cells.

Scientists at Gladstone use iPS cells to better understand, prevent, treat, and cure some of the worlds most devastating diseases.

Gladstone strategically built a diverse community of scientific and clinical experts whose mission is to make groundbreaking scientific discoveries and bring these advances to the clinic. With expertise in stem cell biology, medicine, chemistry, and engineering, Gladstone is uniquely positioned to tackle complex problems from various angles with a highly collaborative, team-based approach.

The Roddenberry Stem Cell Center is an international powerhouse in stem cell research. Established in 2011 with a gift from the Roddenberry Foundation in honor of Eugene Roddenberry, the creator of Star Trek, the center operates with a vision of disrupting basic and translational stem cell science.

The Roddenberry Stem Cell Center provides resources for the Gladstone community to pursue new biomedical discoveries and conduct the rigorous testing needed to translate their most promising findings to the clinic. IPS cells provide unparalleled insight into genetic diseases, empower personalized medicine, and may someday be used to generate tissues and organs for transplantation. The efforts of the Roddenberry Stem Cell Center help Gladstone scientists unlock this tremendous potential of stem cells to advance human health and transform the treatment of disease.

Amyotrophic lateral sclerosis (ALS)

Alzheimers disease

Cardiovascular disease

Diabetes

Huntingtons disease

Liver failure

Macular degeneration

Parkinsons disease

Spinal cord injury

Go here to read the rest:
Roddenberry Stem Cell Center | Gladstone Institutes

June 2020 Global Life Science Reagent Market Research Report is Projected to Witness Considerable Growth by 2027High Throughput Genomics Inc.,…

Life Science Reagent market research report covers and analyses several factors which affect the growth of the Life Science Reagent market. The report on the Life Science Reagent market also provides a detailed analysis of the major aspects of the companies such as financial aspects, research and development and the impact of the COVID-19 pandemic on these companies in the estimated forecasts period. [emailprotected] or call us on +1-312-376-8303. Download Report sample for free ckecl here: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/life-science-reagent-market-report#download_report

Report Scope: Some of the key types analyzed in this report are as follows: Cell Biology Reagents, Animal Models, Recombinant Proteins, Othes

Some of the key applications as follow: Stem Cell Research, DNA Research, RNA Research, Protein Detection, Others

Following are the major key players: High Throughput Genomics Inc., Illumina Inc., Abbott Laboratories, Abcam, Emd Millipore, Biolog, Cell Sciences, Lonza Group Ag, Cell Signaling Technology, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Cepheid Inc., Olympus Corp., Biomyx Technology, Abgent Inc. Request COVID-19 Impact Analysis for Life Science Reagent by clicking on following links: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/life-science-reagent-market-report#download_report

The Life Science Reagent market also determines the introduction of new products and strategies which are used by several companies to reduce the impact of the pandemic of COVID-19. The research report also analyses the value chain analysis of the Life Science Reagent market for the estimated forecast period. It also analyses the risk factors which are associated with the Life Science Reagent market.The worldwide geological [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] analysis of the Life Science Reagent market has furthermore been done cautiously in this report.

Inquiry for Buying or Customization of Report: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/life-science-reagent-market-report#download_report

There are 13 Chapters to display in the Life Science Reagent market: Chapter 1: Introductory overview, Specifications, Classification, and Applications of Life Science Reagent market, Segment by Regions; Chapter 2: Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3: Technical Data and Manufacturing Plants Analysis of Life Science Reagent, Capacity and Commercial Production Rate, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4: Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5: Regional Analysis Chapter 6 and 7: Segment Analysis by Types and Applications Chapter 8: Company profiling of major manufacturers Chapter 9: Market Trend Analysis, Regional Market Trend, Market Trend by Product Type and Applications Chapter 10: Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, 12 and 13: Life Science Reagent sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.. To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/life-science-reagent-market-report#table_of_contents In addition, the report on Life Science Reagent market also provides a detailed analysis of the impact of the several political, environmental, social, technological, legal and economical factors which are likely to affect the Life Science Reagent market. Moreover, the change in the trading policies due to COVID-19 has also been covered in depth.The report also provides a detailed analysis of the financial information, companies which are operating and the key strategies which are used by these players to overcome the impact of the COVID-19 pandemic.

About Us: http://www.cognitivemarketresearch.com/about-us Nicolas Shaw, Sales Manager, Global Business Development, Website: http://www.cognitivemarketresearch.com Email: [emailprotected] or call us on +1-312-376-8303. Address: 20 N State Street, Chicago, Illinois, 60602, United States.

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/pharma-%26-healthcare/life-science-reagent-market-report

View original post here:
June 2020 Global Life Science Reagent Market Research Report is Projected to Witness Considerable Growth by 2027High Throughput Genomics Inc.,...

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy | 2020-07-09 | Press Releases – Stockhouse

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. The Company plans to initiate clinical investigation of FT819 for the treatment of patients with relapsed / refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy. Our unique ability to produce CAR T cells from a clonal master engineered iPSC line creates a pathway for more patients to gain timely access to therapies with curative potential,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. Four years ago, we first set out under our partnership with Memorial Sloan Kettering led by Dr. Michel Sadelain to improve on the revolutionary success of patient-derived CAR T-cell therapy and bring an off-the-shelf paradigm to patients, and we are very excited to advance FT819 into clinical development.”

FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies. Under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, and Head, Gene Expression and Gene Transfer Laboratory at MSK, the Company incorporated several first-of-kind features into FT819 including:

The multi-center Phase 1 clinical trial of FT819 is designed to determine the maximum tolerated dose of FT819 and assess its safety and clinical activity in up to 297 adult patients across three types of B-cell malignancies (CLL, ALL, and NHL). Each indication will enroll independently and evaluate three dose-escalating treatment regimens: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819.

At the American Association for Cancer Research (AACR) Virtual 2020 Meeting, the Company presented preclinical data demonstrating FT819 is comprised of CD8a T cells with uniform 1XX CAR expression and complete elimination of endogenous TCR expression. Additionally, data from functional assessments showed FT819 has antigen-specific cytolytic activity in vitro against CD19-expressing leukemia and lymphoma cell lines that is comparable to that of healthy donor-derived CAR T cells, and persists and maintains tumor clearance in the bone marrow in an in vivo disseminated xenograft model of lymphoblastic leukemia.

Fate Therapeutics has an exclusive license for all human therapeutic use to U.S. Patent No. 10,370,452 pursuant to its license agreement with MSK1, which patent covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC. In addition to the patent rights licensed from MSK, the Company owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

1 Fate Therapeutics has licensed intellectual property from MSK on which Dr. Sadelain is an inventor. As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.

About Fate Therapeutics’ iPSC Product Platform The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates and clinical studies, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, the therapeutic potential of the Company’s product candidates including FT819, and the Company’s clinical development strategy for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of difficulties or delay in the initiation of any planned clinical studies, or in the enrollment or evaluation of subjects in any ongoing or future clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of FT819 may not be replicated in ongoing or future clinical trials or studies, and the risk that FT819 may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com

Original post:
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy | 2020-07-09 | Press Releases - Stockhouse

Coronavirus updates: California to release 8,000 inmates; masks ‘only way’ to prevent another shutdown, Texas Gov. says – USA TODAY

If you thought COVID-19 symptoms couldn't get worse, doctors say a new symptom has emerged. Hallucinations. USA TODAY

A spiking COVID-19 case countis straining Florida's hospital system as nearly half of its intensive care units are at least 90% full, state data shows.

On Thursday, Florida recorded aone-day record of 120 deaths. More than 4,000 people have died there since the start of the pandemic.

Mississippi has also seen a recent strain on its hospitals. Five of the largest medical centers have no ICU bed space for new patients COVID-19 or otherwise and are being forced to turn patients away.

Meanwhile, some states are scaling back reopening guidelines or adding new requirements: Some bars in Nevada will be closing again Friday and restaurants can no longer serve parties more than six people.Kentucky will join the growing list of states that require face coverings in public, too.

In New Mexico, indoor dining at restaurants and breweries will be restricted again starting Monday, and Gov. Michelle Lujan Grisham halted high school sports and said state parks will be closed to out-of-state residents.

Here are some recent developments:

Today's stats:The U.S. has surpassed 3.1 million confirmed cases of COVID-19, the disease caused by the novel coronavirus. More than133,000deaths have been confirmed, according toJohn Hopkins University data. Globally, there have been 12.3 million cases and over 556,000deaths.

What we're reading:ThreeArizona teachers shared a classroom for summer school.They thought they were being "very careful."All threecontracted COVID-19, and one died.The teachers who survived say their colleague's death is a stark reminder of the risks teachers will face if school reopens too soon.

Our live blog will be updated throughout the day. For first-in-the-morning updates,sign upfor The Daily Briefing.

R-0 may be the most important scientific term youve never heard of when it comes to stopping the coronavirus pandemic. USA TODAY

Schools should prioritize safety and rely on local authorities inschool reopening plans, ajoint statementfrom associations of pediatricians, educators and superintendents says.

"Returning to school is important for the healthy development and well-being of children, but we must pursue re-opening in a way that is safe for all students, teachers and staff," the statement says. "Science should drive decision-making on safely reopening schools."

The statement follows a push fromTrump to open schools across the nation andamid a nationwide debate over whether children should return to the classroom.

The statement says the organizations The American Academy of Pediatrics, American Federation of Teachers, the National Education AssociationandThe School Superintendents Association favor a localized approach driven by re experts over a "one-size-fits-all" approach.

In an effort to prevent the spread of COVID-19 in Californiastate prisons, upto 8,000 currently incarcerated people could be released by the end of August, the state's Department of Corrections and Rehabilitation announced Friday.

"Too many people are incarcerated for too long in facilities that spread poor health. Supporting the health and safety of all Californians means releasing people unnecessarily incarcerated and transforming our justice system,"Jay Jordan, Executive Director ofCalifornians for Safety and Justice, said in a press release.

Since the start of the pandemic, the state has releasedabout 10,000 people, according to the state'sDepartment of Corrections.

Activists have repeatedly called on the governor to address the outbreak atSan Quentin prison, where more than 200 staff and more than 1,300 prisoners have active cases, and at least six inmates have died, according to local news reports.

Amid a resurgence of COVID-19 in Georgia, Gov. Brian Kemp announced Friday that the state will reactivate its makeshift coronavirus hospital at a convention center in Atlanta.

The 200-bed temporary hospital at theGeorgia World Congress Centerwas constructed in April but wound down operations at the end of May.

Nearly 3,000 people have died and more than 111,000 people have tested positive for the virus in the state.

At least 47 students at UC Berkeley tested positive for the coronavirus in just one week, and most of the new cases stem from a series of Greek life parties, university officials said.

In a message to the campus community, UniversityHealth Services Medical Director Anna Harte and Assistant Vice Chancellor Guy Nicolette said it was "becoming harder to imagine bringing our campus community back in the way we are envisioning."

"Generally, these infections are directly related to social events where students have not followed basic safety measures such as physical distancing, wearing face coverings, limiting event size, and gathering outside," the officials wrote.

Texas Gov. Greg Abbott begged Texans to mask up in a Friday interview with eastern Texas TV station CBS19, saying face coverings were "the only way"businesses could stay open.

"Its disappointing"that some local officials are refusing to enforce the states mask order, Abbott said. "If we do not all join together and unite in this one cause for a short period of time it will lead to the necessity of having to close Texas back down."

Abbott's ordereffective July 3 requires face masksin public spaces in counties with 20 or more active COVID-19 cases.The order does not apply to people eating,drinking, swimming orexercising or those under 10 years old.

Joel Shannon

West Virginia is among states with the fewest COVID-19 cases, but the state now has the highest coronavirus transmission rate in the country, the head of the state's coronavirus response said Friday.

"The virus is spreading faster person to person in West Virginia right now than in any other state in the country,"Dr. Clay Marsh.The state's "RT value" the average number of people who become infected by an infectious personis the highest in the nation, at 1.37, Marsh said. "We can see that COVID is starting in that logarithmic phase, that compounding phase."

The state has doubled its number of active cases in the last 10-14 days.

Gov. Gretchen Whitmer on Friday expanded Michigan's mask-wearing requirements, effective Monday, saying that wearing masks is the best way to reverse an increase in coronavirus cases.

The order requires the use of face coverings in crowded outdoor spaces and reiterates that individuals are required to wear a face covering whenever they are in an indoor public space. The mandate also requires any business that is open to the public to refuse entry or service to people who refuse to wear a face covering, with limited exceptions.

Paul Egan, Detroit Free Press

Shutting down states in the early days of the US COVID-19 outbreak prevented at least 250,000 deaths and as many as 750,000-840,000 hospitalizations, a new study found. Shelter-in-place orders took about two weeks to show an effect on hospitalizations and three weeks to limit the number of deaths, according to the study by researchers at the University of Iowa and National Bureau of Economic Research.

The authors, who published their results in the journal Health Affairs, also found that deaths from causes other than COVID-19 might have increased if hospitals had become overwhelmed; slowing cases saved those lives, as well, they said.

"These estimates indicate that [stay in place orders] played a key role in flattening the curves not only for cases, but also for deaths and hospitalizations, and eased pressure on hospitals from avoided COVID-19 admissions," the authors conclude.

Karen Weintraub

All 50 states had visitors from Floridathis week, according to data that 15 million U.S. mobile device users provided to the data company Cuebiq. Applying Cuebiqs sample to the whole population, approximately 1.5 million Floridians are now setting up shop in other states.

Residents have left the state in increasing numbers at a time when the crisis there got worse. In early June, just 5% of the states residents appeared in other states. That number has ticked up every week.

Cuebiqs data, which is based on cell phone locations, shows that most interstate visitors from Florida appeared in other parts of the South. About 38% of the states travelers were in Georgia at least once during the week, for example. Alabama, North Carolina, South Carolina and Tennessee also topped the list of destinations for visitors from the hard-struck state.

States outside the region saw big Florida influxes as well. New York, Texas, Pennsylvania and Ohio all had more than 50,000 visits from Florida residents in the most recent week of data, based on an extrapolation of the cell phone location data.

Matt Wynn

New data on the experimental drug remdesivir confirms it can shorten the course of COVID-19 infections and suggests it also can save lives.

Gilead Sciences, Inc., a California pharmaceutical company that makes the drug, revealed data Friday about nearly 400 patients in its late-stage clinical trial.

According to the results, 74% of patients treated with remdesivir had recovered by their 14th day of hospitalization, compared to 59% of those who did not get the drug. Nearly 8% of the patients on remdesivir had died by day 14, versus more than 12% of patients who did not receive it.

The study also found patients who took the drug hydroxychloroquine along with remdesivir fared worse than those on remdesivir alone. The company recommended against using the drugs in combination.

Remdesivir, an antiviral initially developed to treat Ebola, has not yet been approved for widespread use by the U.S. Food and Drug Administration, but it has been given emergency use authorization to treat COVID-19 patients.

Karen Weintraub

Congestion, runny nose, nausea and diarrhea are the four most recent COVID-19 symptoms that the Centers for Disease Control and Prevention added to its growing list of potential signs of the novel coronavirus.

The CDC previously said symptoms include chills, fever, muscle pain, headache, sore throat and a new loss of taste or smell. The agency now lists 11 symptoms on its website.

The additions come as health experts continue to learn more about the disease, and care for very ill COVID-19 patients is improving. Even so, the CDC states the current list doesn't include all possible symptoms for the virus.

Wyatte Grantham-Philips

Fifty-eight Major League Baseball players tested positive for the coronavirus upon reporting to their team, while an additional 13 tested positive after workouts began, according to data released by MLB on Friday.

Perhaps most disconcerting is that 10 teams reported positive test results during what MLB is calling "monitoring testing," meaning one-third of the league's teams had an infected player or staff member after workouts began last week.

Several teams have had workouts halted or curtailed while awaiting test results, and besides those testing positive, players who have come in contact with those testing positive have been temporarily sidelined, as well.

Gabe Lacques

As COVID-19 cases spikeacross, multiple states have taken measures to scale back their reopening plans. Here are some of the last moves:

Read more about states that arepause reopening or take new steps to slow the spread.

A Los Angeles Times report says that researchers are working on an upper-arm injection that would deliverantibody-rich blood plasma of COVID-19 survivors to provide potentially months of protection from the virus.

The approach is similar to one used for other diseases likehepatitis A and could be widely available across the United States, the Times reported.

However, the proposal has received push back from the federal government and pharmaceutical companies, who argue efforts in plasma-based therapy should focus on treating sick people rather than preventing infection, the Times report says.

Dr. Anthony Fauci told the newspaper that the research was promising but more work is needed to show thatcoronavirus antibodies work.

Dr. Anthony Fauci, the nation's top infectious disease expert, said Friday he has not briefed President Donald Trump in at least two months and not seen him in person at the White House since June 2, despite a coronavirus resurgence that has strained hospitals and led several states to pause reopenings.

Fauci told the Financial Times he was "sure" his messages were sent to the president even though the two have not been in close contact in the past several weeks.

The comments from the Trump administration's director of the National Institute of Allergy and Infectious Diseases came as Trump has been critical of Fauci and spoken openly about issues on which they disagree.

In a Thursday interview with Fox News' Sean Hannity, Trump said Fauci had "made a lot of mistakes" but called him a "nice man." Trump also said "most cases" of coronavirus would "automatically cure. They automatically get better."

Fauci also in the FT interview said Trump was incorrect in claiming 99% of coronavirus cases were "harmless" and may have conflated some statistics.

Nicholas Wu

COVID survivors' main symptoms can linger for weeks or even months, causing pain, trouble breathing, nightmares and even organ failure. USA TODAY

Two scientists from the World Health Organization are traveling toBeijing on Friday to lay the groundwork for an investigation into the origins of the new coronavirus.

The researchers,an animal health expert and an epidemiologist, will work with counterparts in China to "look at whether or not it jumped from species to humanand what species it jumped from," WHO spokesperson Dr. Margaret Harris said.

The team will determine the logistics, locations and participantsfor a WHO-led international mission.

The virus was first detected in the central Chinese city of Wuhan late last year. Scientists believe the novel virusoriginated in bats, transferred to another mammal then jumpedto humans.

The Trump administration this week officially began withdrawing the United Statesfrom the WHO, of which President Donald Trump and his advisers have been sharply critical.

Americans are three times as likely to know someone in their community who has been sick with the coronavirus than they did in March, according to a new survey.

More than one-third of Americans (36%) say someone they know outside of their immediate family or work has been sick with the coronavirus, according to a new survey from the Democracy Fund + UCLA Nationscape Project. That number is more than triple the number in mid-March, when it was 11%.

The survey also showed Black (11%) and Latino (11%) Americans are more likely than white Americans (7%) to have had an immediate family member get sick, according to the survey. These racial differences were not apparent in the survey from March.

Rebecca Morin

Nearly half of Florida's intensive-care units are at least 90% full, and more than 1 in 5 are completely full, according to state data.

Hospitals are increasingly strained under COVID-19, andhospitalizations across the state have jumped more than 13% just since July 1. More than 17,100 Floridians have been hospitalized for COVID-19 since the start of the pandemic.

A total of 95 hospital ICUs were at least 90% full Thursday, according to the Florida Agency for Health Care Administration. That's nearly half the 207 ICUs that the agency is tracking. At least 45 hospital ICUs were at capacity, and 46 others had only one bed available in the units.

At least 4,111 people in Florida have died from the virus, according to the state a figure that would have made it the ninth leading cause of death in Florida last year, according to Florida Department of Health statistics. Florida set a one-day record Thursday with 120 deaths. The previous high, 83, was in late April.

Frank Gluck, Fort Myers News-Press

The five largest medical centers in Mississippi have no ICU bed space for new patients coronavirus or otherwise and are being forced to turn patients away, even as COVID-19 continue to surge.

In some cases, patients are being sent to facilities out of state and as far away as New Orleans. In many hospitals, patients admitted to the ER are being forced to spend the night before they receive treatment.

"(Wednesday), five of our biggest hospitals in the state had zero ICU beds. Zero," State Health Officer Dr. Thomas Dobbs said. "Our biggest medical institutions who take care of our sickest patients have no room."

The transition from shelter-in-place to where we currently stand, with the highest number of hospitalizations since the first reported case of the coronavirus virus on March 11, has left the state "wide open," said Dr. Louann Woodward, UMMC vice chancellor for health affairs.

Justin Vicory, Mississippi Clarion Ledger

California is set to become the first state to file a lawsuit against the Trump administration over anew policy that prevents international students from staying in the U.S. if their college or university switches to online-only classes in the fall because of the coronavirus pandemic.

The announcement comes a day after some colleges and universities filed similar lawsuits or announced plans to do so.

The Trump administration revealed its new guidelines in a memo issued by Immigration and Customs Enforcement on Monday. It says that international students will have to leave the country, or face possible deportation, if their schools switch to remote learning, which many have planned to do amid the pandemic.

President Donald Trumps attack on his own health experts guidance for safely reopening schools cracked open for public display a power strugglewithin the administration that has been building for months.

Trump blasted the guidance issued by the Centers for Disease Control and Prevention on Wednesday as very tough & expensive and asking schools to do very impractical things.

But CDC Director Dr. Robert Redfield said on Thursday the guidance would stand, and his staff would provide some new documents to clarify the recommendations.

Theflare-up punctuates a conflict escalating for months, with the nations top scientists publicly sidelined in the Trump administrations initial coronavirus response. Earlier disagreements delayed the release of the reopening guidance for schools and businesses.

Public health leaders who worked at the CDC under prior presidents said they had never seen anything like this weeks open discord."It underminesleadership for everyone involved, said Dr.JeffreyKoplan, a former CDC director."It's public health malpractice to say, 'Open without worrying about anything.'"

Brett Murphy and Letitia Stein

What's actually in the CDC school guidelines?These are the highlights.

Read more:
Coronavirus updates: California to release 8,000 inmates; masks 'only way' to prevent another shutdown, Texas Gov. says - USA TODAY